HeartBeam Study Shows Comparable Accuracy to Standard ECG in Arrhythmia Detection

HeartBeam (NASDAQ: BEAT) announced study results showing no significant differences in detecting atrial fibrillation, atrial flutter and sinus rhythm when its deep learning algorithms were applied to the HeartBeam System versus standard 12-lead ECGs. Data from 201 patients, presented at HRX Live 2025 in Atlanta by Dr. Joshua Lampert of Mount Sinai Heart, demonstrated high accuracy rates in both groups (94.5% HeartBeam vs. 95.5% standard 12-lead).

CEO Rob Eno stated that these findings highlight the potential of HeartBeam's compact, 3D device to expand advanced cardiac monitoring to settings where full 12-lead ECGs may be impractical. The company plans to use these results to support future FDA submissions, building on the technology's existing FDA clearance for arrhythmia assessment received in December 2024.

The implications of this study are significant for cardiac care accessibility. Traditional 12-lead ECGs require specialized equipment and clinical settings, limiting their use to hospitals and medical facilities. HeartBeam's cable-free device, capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG, could enable monitoring in home environments, remote locations, or during emergency situations where immediate cardiac assessment is critical.

This technological advancement addresses a growing need in cardiovascular medicine, where early detection of arrhythmias can prevent serious complications including stroke and heart failure. The comparable accuracy rates suggest that portable monitoring could provide reliable data for clinical decision-making without requiring patients to visit medical facilities. The company's platform technology, protected by over 20 issued patents, represents a shift toward decentralized cardiac health management that could reduce healthcare costs and improve patient outcomes through continuous, accessible monitoring.

The study results, available in the full press release at https://ibn.fm/BDiIa, support HeartBeam's position in the evolving telemedicine and remote patient monitoring landscape. As the 12-lead ECG synthesis software remains under FDA review, these findings provide clinical validation that could accelerate regulatory approval and adoption. The technology's potential to deliver actionable heart intelligence outside medical facilities aligns with broader trends toward personalized, accessible healthcare solutions that empower patients and physicians to manage cardiac conditions more effectively.